Rubicon forays into India's CNS segment with Rs 175.92 crore Arinna buy

Acquires 85% stake in the formulations company valued at Rs 200 crore enterprise value; founder Vivek Seth to retain 15%

Angelini Pharma and Quiver Bioscience team up to tackle genetic epilepsies

Under the deal, Quiver will receive an undisclosed advance payment and research support

IRLAB Therapeutics teams up with Biomia to advance novel CNS drug candidates

GenSight Biologics gets early access nod for candidate gene therapy in Israel

Applications include detailed scientific rationale and supporting clinical evidence

MIRA Pharmaceuticals announces collaboration with Pharmaseed

Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024

PrecisionLife announces strategic CNS drug development collaboration with Nanopharmaceutics

Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio

Akums partners with Leiutis and Biophore for developing products for multiple therapies

The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas